ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

Author： Borroni B.   Colciaghi F.   Pastorino L.   Archetti S.   Corsini P.   Cattabeni F.   Di Luca M.   Padovani A.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.12, Iss.3, 2002-06, pp. : 195-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apolipoprotein E4 (ApoE4) genotype and/or gender do not appear to predict a response to donepezil in patients with mild-to-moderate Alzheimer's disease

By  

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease

By Martiskainen Henna  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 7, 2013-10 ,pp. : 781-794

Informa Healthcare

Access to resources Recommend Favorite

Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease

By Van Dam Debby   Coen Katrien   De Deyn Peter  

Psychopharmacology, Vol. 197, Iss. 1, 2008-03 ,pp. : 37-43

Springer Publishing Company

Access to resources Recommend Favorite

The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 21, Iss. 1, 2015-01 ,pp. : 114-120

Bentham Science Publishers

Access to resources Recommend Favorite

Rosiglitazone appears to improve cognition in patients with Alzheimer's disease who do not possess an ApoE4 gene variant

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite